The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Dafiro HCT



Novartis Europharm LimitedEU/1/09/574/1-12

Main Information

Trade NameDafiro HCT
Active SubstancesAmlodipine besylate
Hydrochlorothiazide
Valsartan
Dosage FormFilm-coated tablet
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/09/574/1-12

Group Information

ATC CodeC09DX Angiotensin II antagonists, other combinations
C09DX01 valsartan, amlodipine and hydrochlorothiazide

Status

Authorised/WithdrawnAuthorised
Licence Issued04/11/2009
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back